What is Petros Pharmaceuticals, Inc. (PTPI) stock price today?

Petros Pharmaceuticals, Inc. (PTPI) is currently trading at $0.00.

What is PTPI P/E ratio?

Petros Pharmaceuticals, Inc.'s P/E ratio is 0.00. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is PTPI return on equity (ROE)?

Petros Pharmaceuticals, Inc.'s return on equity (ROE) is 66.67%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Petros Pharmaceuticals, Inc.'s market cap?

Petros Pharmaceuticals, Inc. has a market capitalization of $131354.

OTC · Drug Manufacturers - Specialty & Generic

Petros Pharmaceuticals, Inc. (PTPI) Stock

$0.00 OTC: PTPI Healthcare

Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions.

Valuation

Metric	Value
Price	$0.00
Market Cap	$131354
P/E Ratio	0.00
P/B Ratio	0.04
P/S Ratio	0.00
EPS (TTM)	$-1.56
52-Week High	$0.03
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	66.67%
ROA	40.00%
ROCE	-237.69%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	2.50

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$8.0M	$6.0M	$6.0M	$5.0M	$0
Operating Profit	$-18.0M	$-20.0M	$-14.0M	$-18.0M	$-5.0M
Net Profit	$-9.0M	$-20.0M	$-8.0M	$-14.0M	$2.0M
EPS	$-8.25	$-9.68	$-6.35	$-3.34	$-1.56
Op Margin	-231.1%	-332.4%	-233.9%	-345.8%	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$67.0M	$32.0M	$34.0M	$11.0M	$5.0M
Total Liabilities	$32.0M	$16.0M	$21.0M	$18.0M	$2.0M
Cash	$24.0M	$9.0M	$13.0M	$4.0M	$5.0M
Borrowings	$0	$10.0M	$8.0M	$7.0M	$0

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-12.0M	$-13.0M	$-8.0M	$-3.0M	$-7.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$4.0M	$0	$15.0M	$1.3B	$0
Net Cash Flow	$7.0M	$-14.0M	$4.0M	$-10.0M	$1.0M
Free Cash Flow	$-12.0M	$-13.0M	$-8.0M	$-3.0M	$-7.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	1.18
FCF Yield	-4460.38%
Quick Ratio	1.68
Interest Coverage	0.00
Return 1Y	-88.52%
Return 3Y	-100.00%
Return 5Y	-100.00%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CCMConcord Medical Services Holdings Limited	$4.32	+7.20%	-0.03	$629052	0.00%
CELUCelularity Inc.	$0.75	+0.13%	-0.20	$21.74M	0.00%
HEPAHepion Pharmaceuticals, Inc.	$0.05	+17.78%	-0.21	$617116	0.00%
IVF	$0.96	-4.09%	-0.01	$1.71M	0.00%
LIXT	$7.21	-6.00%	-5.30	$89.11M	0.00%

About Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.

Petros Pharmaceuticals, Inc. (PTPI) stock trades at $0.00 with a market capitalization of $131354. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.04, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.03, and currently trades 100.0% below its 52-week high.

On profitability, Petros Pharmaceuticals, Inc. generates a return on equity (ROE) of 66.67% — well above the market average, a sign of a high-quality business, return on capital employed of -237.69%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.petrospharma.com